12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Company News  |  Deals

Lycera, Merck deal

The companies partnered to discover, develop and commercialize small molecules against undisclosed targets for autoimmune diseases. Lycera will receive an undisclosed upfront payment and research funding and is eligible to receive more than $300 million in milestones, plus royalties and additional sales milestones....

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >